Viekira pak (copackaged), Viekirax(ombitasvir)
Technivie, Viekira, Viekirax (ombitasvir) is a small molecule pharmaceutical. Ombitasvir was first approved as Viekira pak (copackaged) on 2014-12-19. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ombitasvir
+
Paritaprevir
+
Ritonavir
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hepatitis c | — | D006526 | B19.2 |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Xr, Abbvie | |||
| 9333204 | 2035-01-02 | DP | U-1889 |
| 9744170 | 2035-01-02 | DP | U-1889 |
| 10105365 | 2035-01-02 | DP | U-1889 |
| 10201541 | 2032-05-17 | DP | |
| 10201584 | 2032-05-17 | U-1889 | |
| Dasabuvir Sodium / Ombitasvir / Paritaprevir / Ritonavir, Viekira Pak (Copackaged), Abbvie | |||
| 9629841 | 2033-10-18 | DP | U-1753 |
| 10201542 | 2033-10-18 | DP | U-1753 |
| 8466159 | 2032-09-04 | U-1637 | |
| 8492386 | 2032-09-04 | U-1840 | |
| 8680106 | 2032-09-04 | U-1637 | |
| 8685984 | 2032-09-04 | U-1840 | |
| 8691938 | 2032-04-13 | DS, DP | |
| 8686026 | 2031-06-09 | DP | |
| 8420596 | 2031-04-10 | DS, DP | |
| 9044480 | 2031-04-10 | U-1638 | |
| 9006387 | 2030-06-10 | U-1687 | |
| 8642538 | 2029-09-10 | DS, DP | U-1638 |
| 8188104 | 2029-05-17 | DS, DP | U-1636 |
| 8501238 | 2028-12-19 | DS, DP | U-1636 |
| 9139536 | 2028-11-09 | U-1753 | |
| 8268349 | 2024-08-25 | DP | |
| 8399015 | 2024-08-25 | DP | |
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 4 | 21 | 37 | 10 | 31 | 97 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 2 | 21 | 37 | 6 | 31 | 91 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 19 | 37 | 5 | 29 | 86 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 19 | 32 | 9 | 26 | 82 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 15 | 29 | 1 | 19 | 61 |
| Infections | D007239 | EFO_0000544 | — | — | 10 | 24 | 1 | 1 | 33 |
| Hepacivirus | D016174 | — | — | — | 3 | 8 | 1 | 1 | 12 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 3 | 2 | 2 | 2 | 7 |
| Coinfection | D060085 | — | — | — | 2 | 2 | 2 | 1 | 5 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 3 | 2 | — | 5 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 9 | 14 | — | 1 | 22 |
| Communicable diseases | D003141 | — | — | — | 9 | 15 | — | — | 21 |
| Fibrosis | D005355 | — | — | — | 2 | 8 | — | 1 | 10 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 2 | 6 | — | 2 | 9 |
| Virus diseases | D014777 | — | B34 | — | 4 | 5 | — | 1 | 9 |
| Hepatitis b | D006509 | — | — | 1 | 3 | 2 | — | — | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 1 | — | 1 | 2 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | — | 1 | 1 | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | 1 | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemoglobinopathies | D006453 | — | D58.2 | — | — | — | — | 1 | 1 |
| Homozygote | D006720 | — | — | — | — | — | — | 1 | 1 |
| Hiv | D006678 | — | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ombitasvir |
| INN | ombitasvir |
| Description | Ombitasvir is a dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. It has a role as an antiviral drug and a hepatitis C virus nonstructural protein 5A inhibitor. It is a member of pyrrolidines, a carbamate ester, an aromatic amide and a dipeptide. It is functionally related to a Val-Pro. |
| Classification | Small molecule |
| Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc([C@@H]2CC[C@@H](c3ccc(NC(=O)[C@@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)cc3)N2c2ccc(C(C)(C)C)cc2)cc1)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 1258226-87-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3127326 |
| ChEBI ID | 85183 |
| PubChem CID | 54767916 |
| DrugBank | — |
| UNII ID | 2302768XJ8 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Viekira – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,428 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,807 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use